Literature DB >> 457278

Hepatitis B e-antigen and its correlation with other serological markers in chimpanzees.

C M Ling, I K Mushahwar, L R Overby, K R Berquist, J E Maynard.   

Abstract

Three chimpanzees experimentally infected with hepatitis B virus, and another three chimpanzees that were hepatitis surface antigen carriers, were studied for the presence of viral antigens and humoral immune responses. Quantitative analyses of hepatitis B surface and e-antigens in sequential serum samples at early acute stages revealed cyclic oscillations of these two antigens following a synchronous pattern. Similar analyses of anti-e-antigen and anti-hepatitis B core antigen antibodies from the three experimentally infected primates indicated that peak titers of these two antibodies occurred as surface antigen decreased to undetectable levels. Of the three surface-antigen carriers, two were positive for e-antigen and one was positive for e-antigen antibody for the entire course of surveillance (8, 9, and 22 months, respectively).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 457278      PMCID: PMC414308          DOI: 10.1128/iai.24.2.352-356.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Hepatitis B e antigen and infectivity of hepatitis B virus.

Authors:  T Shikata; T Karasawa; K Abe; T Uzawa; H Suzuki; T Oda; M Imai; M Mayumi; Y Moritsugu
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

2.  "e" Antigen, Dane particles, and serum DNA polymerase activity in HBsAg carriers.

Authors:  S H Hindman; C R Gravelle; B L Murphy; D W Bradley; W R Budge; J E Maynard
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

3.  Detection of e antigen during acute and chronic hepatitis B virus infections in chimpanzees.

Authors:  E Tabor; R J Gerety; L F Barker
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

4.  Incidence and meaning of the "e" determinant among hepatitis-B-antigen positive patients with acute and chronic liver diseases. Report from the Copenhagen Hepatitis Acuta Programme.

Authors:  J O Nielsen; O Dietrichson; E Juhl
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

5.  New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants.

Authors:  L O Magnius; J A Espmark
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

6.  Prevalence of hepatitis B e antigen and its antibody as detected by radioimmunoassays.

Authors:  I K Mushahwar; L R Overby; G Frosner; F Deinhardt; C M Ling
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

7.  Seroconversion from hepatitis B e antigen to anti-HBe in acute hepatitis B virus infection.

Authors:  T Aikawa; H Sairenji; S Furuta; K Kiyosawa; T Shikata; M Imai; Y Miyakawa; Y Yanase; M Mayumi
Journal:  N Engl J Med       Date:  1978-02-23       Impact factor: 91.245

8.  Dane particles, DNA polymerase, and e-antigen in two different categories of hepatitis B antigen carriers.

Authors:  E Nordenfelt; L Kjellén
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

9.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure.

Authors:  H J Alter; L B Seeff; P M Kaplan; V J McAuliffe; E C Wright; J L Gerin; R H Purcell; P V Holland; H J Zimmerman
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

10.  Host specificity of a serum marker for hepatitis B: evidence that "e antigen" has the properties of an immunoglobulin.

Authors:  A R Neurath; N Strick
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

View more
  1 in total

1.  Serological testing for hepatitis B in male homosexuals: special emphasis on hepatitis B e antigen and antibody by radioimmunoassay.

Authors:  B L Murphy; M T Schreeder; J E Maynard; S C Hadler; M J Sheller
Journal:  J Clin Microbiol       Date:  1980-03       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.